TAUVID
Peakflortaucipir f-18
NDAINTRAVENOUSSOLUTIONPriority Review
Approved
May 2020
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 3h ago · AI intelligence enriched 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TAUVID (flortaucipir F-18) is a tau-targeted PET imaging agent used to visualize tau pathology in the brain. It is administered intravenously as a diagnostic imaging solution to support evaluation of patients with cognitive impairment, suspected neurodegenerative disease, or research applications. The agent binds to tau aggregates, enabling clinicians to assess tau burden as a biomarker of neurodegeneration.
Peak5.6 years to LOE
Product is in peak commercial phase with no direct competitors, suggesting stable but specialized demand; team composition likely remains lean given narrow diagnostic niche.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TAUVID roles are specialized and concentrate on medical affairs, imaging expertise, and healthcare provider education rather than broad-based field sales. Professionals joining this product should expect deep clinical engagement with neurology and radiology communities, differentiated from traditional pharma sales models.
Medical Science LiaisonImaging Specialist
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.